Similar articles for PMID: 9724660

Year	Number of Results
1968	1
1973	1
1988	1
1989	3
1991	1
1993	3
1994	1
1995	1
1996	5
1997	5
1998	6
1999	9
2000	8
2001	6
2002	10
2003	13
2004	10
2005	3
2006	3
2007	9
2008	7
2009	13
2010	9
2011	19
2012	16
2013	14
2014	24
2015	13
2016	17
2017	14
2018	16
2019	12
2020	63
2021	9

1

Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants.

[No authors listed] [No authors listed] Pediatrics. 1998 Sep;102(3):531-7. Pediatrics. 1998. PMID: 9724660

2

Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

[No authors listed] [No authors listed] Pediatrics. 1998 Sep;102(3 Pt 1):531-7. Pediatrics. 1998. PMID: 9738173 Clinical Trial.

3

Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.

Lacaze-Masmonteil T, Rozé JC, Fauroux B; French Pediatricians' Group of Sunagis Patients' Name-Based Programs. Lacaze-Masmonteil T, et al. Pediatr Pulmonol. 2002 Sep;34(3):181-8. doi: 10.1002/ppul.10175. Pediatr Pulmonol. 2002. PMID: 12203846

4

Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?

Hashmi NA, Cosgrove JF, MacMahon P. Hashmi NA, et al. Ir Med J. 2000 Dec;93(9):284. Ir Med J. 2000. PMID: 11209917

5

Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.

Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J; IRIS Study Group. Pedraz C, et al. Pediatr Infect Dis J. 2003 Sep;22(9):823-7. doi: 10.1097/01.inf.0000086403.50417.7c. Pediatr Infect Dis J. 2003. PMID: 14506376

6

Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.

Romero JR. Romero JR. Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S46-54. doi: 10.1097/01.inf.0000053885.34703.84. Pediatr Infect Dis J. 2003. PMID: 12671452

7

Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.

Paes B, Steele S, Janes M, Pinelli J. Paes B, et al. Curr Med Res Opin. 2009 Jul;25(7):1585-91. doi: 10.1185/03007990902929112. Curr Med Res Opin. 2009. PMID: 19469698

8

Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group.

Groothuis JR, Simoes EA, Hemming VG. Groothuis JR, et al. Pediatrics. 1995 Apr;95(4):463-7. Pediatrics. 1995. PMID: 7700741 Clinical Trial.

9

Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.

Giebels K, Marcotte JE, Podoba J, Rousseau C, Denis MH, Fauvel V, Laberge S. Giebels K, et al. Pediatr Pulmonol. 2008 Feb;43(2):169-74. doi: 10.1002/ppul.20751. Pediatr Pulmonol. 2008. PMID: 18085710

10

Prevention of respiratory syncytial virus infection among Puerto Rican infants.

Winchester L, García L, García I, Concepción CB. Winchester L, et al. P R Health Sci J. 2002 Sep;21(3):191-3. P R Health Sci J. 2002. PMID: 12243108 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed